Massachusetts-based manufacturer of innovative dialysis products, NxStage Medical, Inc. NXTM, will present four new abstracts demonstrating clinical results during the National Kidney Foundation's Spring Clinical Meeting in Dallas, TX.
Three of the abstracts seek to substantiate that daily home hemodialysis (DHHD) patients who use the NxStage System One can achieve improved survival, reduced cardiovascular hospital readmissions, and increased transplantation.
The fourth abstract contains detailed results from the study conducted by NxStage Medical which propelled the U.S. Food and Drug Administration (FDA) clearance of its home nocturnal hemodialysis product – System One.
The new data shows that the risk of death is 29% lower in patients using DHHD than that of patients receiving conventional in-center hemodialysis (IHD). The abstracts also highlight that patients using DHHD have 15% lower risk of 30-day readmission in hospital than peritoneal dialysis (PD) patients and 27% lower than IHD patients. The study also reflects 37% greater incidence of transplant among DHHD patients when compared to PD patients and 22% greater than IHD patients.
The fourth abstract displays the positive results of 58 patients suffering from End Stage Renal Disease (ESRD), who received home nocturnal hemodialysis (NHD) with the NxStage System One. The study enrolled patients and transitioned them to home NHD from DHHD.
The results obtained hints at increased clearance, improved phosphorus control, and better safety and efficacy comparable to DHHD.
In Dec 2014, Nxstage Medical secured the U.S. FDA approval for System One to perform hemodialysis overnight while the patient is at home. This made it the first and only hemodialysis machine cleared for this indication.
We are impressed with the company’s latest developments with respect to System One. We feel this will eventually help Nxstage Medical significantly expand its existing customer base and subsequently drive top-line growth.
Zacks Rank
Currently, Nxstage Medical has a Zacks Rank #3 (Hold). Better-ranked stocks in the medical sector are SurModics SRDX, Abaxis ABAX and Capricor Therapeutics CAPR. While SurModics sports a Zacks Rank #1 (Strong Buy), Abaxis and Capricor Therapeutics hold a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Be the first to comment